Advanced searches left 3/3

Vitamin K - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 09 July 2022

* If you want to update the article please login/register

Vitamin K Supplementation Study in Healthy Volunteers (Aim 2B)

In populations with characterized CYP4F2*3 genotype, the investigators will investigate the effects of vitamin K supplementation on two biomarkers of hepatic vitamin K concentration. Following a 10-day period of vitamin K supplementation in healthy volunteers, the investigators will investigate a correlation between our novel biomarkers of long-term and short-term hepatic vitamin K concentration and CYP4F2*3. At the diagnostic locus for the supplementation phase of the study, the PI and Research Coordinator will analyze the genotyping results and then select 14 individuals with either a homozygous CYP4F2*3 genotype or a heterozygous CYP4F2*1/*3 genotype, as well as a geographically matched group of 14 people with a homozygous CYP4F2*1 genotype at the diagnostic locus. We'll get cheek cells from a cotton swab and isolate DNA as well as a CYP4F2*1 and CYP4F2*3 alleles of the Buccal Swab. Vitamin K Supplementation: For ten days in a row, research participants who were chosen for the supplementation study based on CYP4F2 genotype will be given 1-mg/day phylloquinone. Sample Collection: After an overnight fast from d1 to d5 and d10 and d10 vitamin K supplementation for ten days, sample collection for the supplementation study will be collected. Measurement of Plasma Factor II Proteoforms (LC-MS/MS): Proteoforms is the most suitable test subject for measuring plasma Factor II Proteoforms. Urinary K-Acid I and II: Quantitation of K-Acid I and II, assays by the investigators have recently developed a validated LC-MS/MS assay.

Source link: https://clinicaltrials.gov/ct2/show/NCT04450212


Effect of Jarlsberg Cheese Compared to Cheese Without Vitamin K2 Regarding Increased Osteocalcin Level in Healthy Women

A qualitative investigation will be conducted into the recruitment of HV women who met the inclusion criteria for the study. The participants receive a study identification number during this first clinical study in the study, which was denoted as Day 0 on the study. With clinical trials every third week, the HVs referred to Camembert cheese will be switched to daily intake of Jarlsberg cheese after 6 weeks. Participants in the 6 weeks of daily consumption of Jarlsberg cheese will either be invited to participate in the cheese de-escalation study or an extended study of 6 weeks with unchanged Jarlsberg cheese doses. In the de-escalation study, the osteocalcin level from screening to 6 weeks of Jarlsberg cheese intake would not be included. The first 12 HVs completed 6 weeks with daily intake of Jarlsberg cheese, contributing to an increase in the osteocalcin level from baseline to the de-escalation study HV-Jarlsberg/IB. For an additional 6 weeks with clinical monitoring every third week, the HVs included in the extended portion of this research will get unchanged daily dose of Jarlsberg cheese. Ideally, the HVs have switched to Jarlsberg cheese, and they may be able to participate in a research component aimed at determining the maintaining dose obtained in the HV-Jarlsberg/IB study. Added to the K2 variants MK-7, 8, 9, 9 and vitamin K1, the osteocalcin in serum, with carboxylated and under carboxylated Osteocalcin and the ratio OR = [Carboxylated] osteocalcin, and serum's ratio OR = [Carboxylated / Under Carboxylated] osteocalcin and the ratio OR = [Carboxylated] osteocalcin and the ratio OR = [Carboxylated.

Source link: https://clinicaltrials.gov/ct2/show/NCT04189796


A Phase 2, Double Blind, Randomized, Placebo-controlled Clinical Trial to Investigate the Safety and Effects of Oral Vitamin K2 Supplementation in COVID-19

The outbreak of coronavirus 2019 disease has a major effect on health care around the world. Coagulation is a complex mixture of clot promoting and dissolving procedures in which vitamin K plays a key role. Matrix Gla protein is also vitamin K-dependent, but not involved in intravascular coagulation. Inactive MGP is a robust biomarker of extrahepatic vitamin K status because it is inversely related to vitamin K deficiency, particularly in pathological conditions of elevated vitamin K use. Vitamin K1 and vitamin K2 are also present in food, as shown in nature. Vitamin K-dependent proteins that have not been carboxylated have yet to be carboxylated are a useful measure of vitamin K1 and K2's functional deficit. Circulating dp-ucMGP results can best be described as a result of the total extrahepatic vitamin K deficiency, which is determined by the amount of vitamin K needed to carboxylate all the uncarboxylated vitamin K-dependent proteins in the body. Vitamin K deficiency is a common indication of Hepatic vitamin K deficiency (II). Hypothesis It is hypothesized that vitamin K supplementation may have favorable results on both pulmonary damage and coagulation abnormalities in COVID-19 patients. Objective The aim of the KOVIT trial was to determine the effectiveness of oral vitamin K2 supplementation in patients suffering from COVID-19, which requires hospitalization.

Source link: https://clinicaltrials.gov/ct2/show/NCT04770740

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions